Skip to content

Study · Animal study (in vivo) · mouse · 2018

7 results

Exogenous nicotinamide adenine dinucleotide regulates energy metabolism via hypothalamic connexin 43.

Roh E, Park JW, Kang GM, Lee CH, Dugu H, Gil SY, Song DK, Kim HJ, Son GH, Yu R, Kim MS

Metabolism: clinical and experimental1 Sept 2018Cited by 22 (Europe PMC)

PMID30179604 (opens in a new tab)DOI10.1016/j.metabol.2018.08.005 (opens in a new tab)PepBankPUB-30179604
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, central and peripheral NAD administration suppressed fasting-induced hyperphagia.

    In plain wordsIn mice, central and peripheral NAD administration reduced overeating after fasting.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseFasting-induced hyperphagia
    Study

    mousen: not reported in source

    Fasting mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · central and peripheralAs given in this study (mouse).

    Source sentences

    Summary
    Central and peripheral NAD administration suppressed fasting-induced hyperphagia and weight gain in mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, central and peripheral NAD administration suppressed weight gain.

    In plain wordsIn mice, central and peripheral NAD administration reduced weight gain.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseWeight gain
    Study

    mousen: not reported in source

    Fasting mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · central and peripheralAs given in this study (mouse).

    Source sentences

    Summary
    Central and peripheral NAD administration suppressed fasting-induced hyperphagia and weight gain in mice.
  3. 03LabIn vitro (cells)Mechanism

    In N1 hypothalamic neuronal cells, extracellular NAD import depended on connexin 43 but not CD73.

    In plain wordsIn cells, NAD import depended on connexin 43 but not CD73.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    Not applicableNAD import mechanism
    Study

    n: not reported in source

    N1 hypothalamic neuronal cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Extracellular NAD was imported into N1 hypothalamic neuronal cells in a connexin 43-dependent and CD73-independent manner.
  4. 04LabIn vitro (cells)Mechanism

    In the hypothalamic neuronal experiments, NAD suppressed NPY transcriptional activity through SIRT1 and FOXO1.

    In plain wordsIn cells, NAD suppressed NPY transcriptional activity through SIRT1 and FOXO1.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseNPY transcriptional activity
    Study

    n: not reported in source

    Hypothalamic neuronal cells
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous NAD suppressed NPY and AgRP transcriptional activity, which was mediated by SIRT1 and FOXO1.
  5. 05LabIn vitro (cells)Mechanism

    In the hypothalamic neuronal experiments, NAD suppressed AgRP transcriptional activity through SIRT1 and FOXO1.

    In plain wordsIn cells, NAD suppressed AgRP transcriptional activity through SIRT1 and FOXO1.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseAgRP transcriptional activity
    Study

    n: not reported in source

    Hypothalamic neuronal cells
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exogenous NAD suppressed NPY and AgRP transcriptional activity, which was mediated by SIRT1 and FOXO1.

Studies that did not test the peptide alone2

In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  1. 06AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Mechanism

    In mice, connexin 43 inhibition blocked hypothalamic NAD uptake.

    In plain wordsIn mice, connexin 43 inhibition blocked hypothalamic NAD uptake.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseHypothalamic NAD uptake inhibition
    Study

    mousen: not reported in source

    Fasting mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Consistent with the in vitro data, inhibition of hypothalamic connexin 43 blocked hypothalamic NAD uptake and NAD-induced anorexia.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  2. 07AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Mechanism

    In mice, connexin 43 inhibition blocked NAD-induced anorexia.

    In plain wordsIn mice, connexin 43 inhibition blocked NAD-induced appetite suppression.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseNAD-induced anorexia inhibition
    Study

    mousen: not reported in source

    Fasting mice
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Consistent with the in vitro data, inhibition of hypothalamic connexin 43 blocked hypothalamic NAD uptake and NAD-induced anorexia.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.